Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Malabsorption Disorders Clear all
Completed Phase 3 Interventional Results available

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

NCT02949362
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide, SOC
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 15, 2026, 2:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk

NCT05660278
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 15, 2026, 2:43 PM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease

NCT01297933
View directory record Official record
Conditions
Cholestasis, Short Bowel Syndrome
Interventions
Omegaven
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 15, 2026, 2:43 PM EDT
Enrolling by invitation No phase listed Observational

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT05635747
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption
Interventions
Relizorb Enzyme Cartridge
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Genepro Generation 3 Protein Bioavailability Compared to Whey Protein

NCT04615858
View directory record Official record
Conditions
Absorption; Disorder, Protein, Protein Malabsorption, Protein Intolerance
Interventions
Genepro Generation 3 Protein, Whey Protein
Dietary Supplement
Lead sponsor
Musclegen Research, Inc.
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cary, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

NCT02954458
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
TED, SOC, Syringe, Needle
Drug · Other · Device
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 15, 2026, 2:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis (EUS-CPN) for Chronic Pancreatitis

NCT04403074
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Celiac Plexus Neurolysis
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome

NCT02355743
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
rtPA lock therapy
Drug
Lead sponsor
Lynn Malec
Other
Eligibility
6 Months to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 15, 2026, 2:43 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

NCT06807463
View directory record Official record
Conditions
Celiac Disease
Interventions
TEV-53408, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Murrieta, California • Colorado Springs, Colorado • Inverness, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome

NCT00767364
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Biological
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
6 Weeks to 18 Months
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

NCT05636293
View directory record Official record
Conditions
Celiac Disease
Interventions
Ritlecitinib, Placebo, Gluten
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Use of Pancreatic Enzymes in Short Bowel Syndrome

NCT03097029
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Pancreatic Enzyme
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 15, 2026, 2:43 PM EDT
No Longer Available No phase listed Expanded access

Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis

NCT02148146
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

NCT01900288
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions
HPN Group Clinic Appointments using Mobile Devices (experimental), Mobile Device Access (placebo)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
13 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

NCT03409796
View directory record Official record
Conditions
Celiac Disease
Interventions
Gluten
Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

NCT02199496
View directory record Official record
Conditions
Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
Interventions
Stelara (ustekinumab)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Not applicable Interventional

Sham Feeding Post-operative Infants

NCT03350022
View directory record Official record
Conditions
Newborn Morbidity, Oral Aversion, Gastroschisis, Bowel Obstruction, Short Bowel Syndrome
Interventions
Sham Feeding
Procedure
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 2 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 15, 2026, 2:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Perceived Lactose Intolerance

NCT01331265
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
3,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance

NCT01113619
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28 or placebo
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 15, 2026, 2:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gluten-Free Diet in Patients With Gluten Sensitivity and Cerebellar Ataxia

NCT00006492
View directory record Official record
Conditions
Celiac Disease, Cerebellar Ataxia, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 15, 2026, 2:43 PM EDT
Recruiting No phase listed Observational

Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling Device

NCT06927011
View directory record Official record
Conditions
Colon Cancer
Interventions
Capscan
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
20 Years to 85 Years
Enrollment
20 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 15, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

NCT02734810
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase Powder for Oral Solution
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
28 Days and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
21
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 15, 2026, 2:43 PM EDT